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EDITORIAL
The growing role for the cyclin kinase inhibitor p27Kh1)l in renal
disease
There has been great excitement in the study of cell cycle
regulatory proteins in the past five years, first in non-renal
and recently in renal cells. The original paradigm was
simple, namely that the nuclear proteins called cyclins
activated specific cyclin-dependent kinases (CDKs) during
each phase of the cell cycle, and the activated cyclin-CDK
complexes are required for DNA synthesis and prolifera-
tion [1]. A second paradigm has developed more recently
since the identification of two families of cyclin kinase
inhibitors. Cyclin kinase inhibitors (CKI) bind to and
inactivate cyclin-CDKs, thereby arresting the cell cycle and
inhibiting proliferation [2J. This latter model viewed the
role of cyclin kinase inhibitors as limited to cell prolifera-
tion. However, what has become quite evident is that each
cell type is governed by specific cyclin kinase inhibitors, and
perhaps more interesting as shown by Hannken et al in this
edition of Kidney International [31, that the biological
functions of CIU are more diverse than originally pre-
dicted.
There is now abundant evidence available that cell
proliferation is central to several types of renal diseases,
thus making the potential to alter the proliferative response
of great interest to both clinical and experimental neph-
rologists. The CKI p27' (p27) is a nuclear protein that
binds to and inhibits both Gi and S phase cyclin-CDK
complexes. A role for p27 has been well established in
glomerular cell proliferation in vitro. Growth factor-in-
duced mesangial cell proliferation is associated with de-
creased levels of p27, and further lowering p27 levels with
antisense oligonucleotides augments the proliferative re-
sponse [4]. In contrast, in some cells such as fibroblasts and
vascular smooth muscle cells, certain growth factors induce
proliferation without an alteration in p27 levels. In vivo, the
onset of immune-mediated mesangial cell proliferation in
experimental glomerutonephritis (Thyl model) also coin-
cides with a decrease in p27 levels [5]. Thus, mesangial cell
proliferation requires a decrease in p27 levels, and the
inhibitory threshold to growth factor-induced proliferation
is determined by p27.
Unlike the mesangial cell, immunemediated injury to
the visceral glomerular epithelial cell or podocyte (GEC) in
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membranous nephropathy (passive Heymann nepliritis
model) is characterized by an apparent lack of GEC
proliferation, which may underlie the development of pro-
gressive glomerutosclerosis [6]. In contrast to mesangial
proliferative glonierulonephritis, immune-mediated injury
to the GEC in experimental membranous nepliropathy is
accompanied by an increase in p27 levels. In addition to the
increased expression, p27 has been demonstrated to bind to
and inhibit CDK2, the cell cycle protein essential for DNA
synthesis. Thus, p27 may be responsible not only for
facilitating proliferation of mesangial cell but also for
limiting proliferation of GEC in response to injury [7]. That
p27 plays a functional role in inflammatory renal disease
has recently been established as well. Both glomerular and
tubular cell proliferation were markedly increased in
p27—I— mice compared to controls following both im-
mune- and non-immune-mediated forms of injury [8].
Could p27 have biological functions beyond regulating
renal cell proliferation? The study by Hannken et al
highlights a second function for p27 in mediating renal cell
hypertrophy [3). Engagement of the cell cycle is accompa-
nied by an increase in protein content, due to de novo
protein synthesis. Cell hypertrophy is defined as an increase
in protein to DNA ratio. Therefore, one mechanism un-
derlying cell hypertrophy may be inhibition of DNA syn-
thesis during the early phase of the cell cycle when protein
synthesis is increased.
A rote for cyclin kinase inhibitors has been shown in
certain forms of renal hypertrophy. Forced overexpression
of the cyclin kinase inhibitors p21" and p27 induces
hypertrophy in mesangial cells in vitro [9]. Glucose-induced
mesangial cell hypertrophy in vitro is associated with in-
creased levels of 2j WAFI [10] and p27 [11], and
lowering p27 with antisense abrogates glucose-induced
hypertrophy in cultured mesangial cells [11]. Furthermore,
p21'" [101 and p27 [121 are increased during gb-
merular hypertrophy in experimental diabetic nephropathy.
Wolf and colleagues previously demonstrated the novel
finding that angiotensin Il-mediated hypertrophy in tubular
epithelial cells was associated with increased p27 levels,
while lowering p27 prevented hypertrophy [13]. En the
current study, Hannken et al have extended these observa-
tions and identified certain intracellular signating pathways
that increase p27 expression following angiotensin II stim-
ulation [3], providing new insights into how certain growth
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membra nous nephropathy (passive Heyman  nephr tis
model) is characterized by an a parent lack of GEC
proliferation, which may underlie the development of pro-
gressive glomerulosclero is [6]. In contrast to mesangial
proliferative glomerulonephritis, i mune-mediated injury
to the GEC in experimental membranous nephropathy is
accompanied by an increase in p27 levels. In addition to the
increased expression, p27 has been demonstrated to bind to
and inhibit CDK2, the cell cycle protein essential for DNA
synthe is. Thus, p27 may be responsible not only for
fac litating proliferation of mesangial cell but also for
limiting proliferation of GEC in response to injury [7]. That
p27 plays a functional role in infla matory renal disease
has recently been established as well. Both glomerular and
tubular cell proliferation were markedly increased in
p27—I— mice compared to controls following both im-
mune- and non-i mune-mediated forms of injury [8].
Could p27 have bi logical functions beyond regulating
renal cell proliferation? The study by Ha nken et al
highlights a second function for p27 in mediating renal cell
hype trophy [31. Engagement of the cell cycle is accompa-
nied by an increase in protein content, due to de novo
protein synthe is. Cell hype trophy is defined as an increase
in protein to DNA ratio. Therefore, one mechanism un-
derlying cell hype trophy may be inhib tion of DNA syn-
the is during th  early phase of the cell cycle when protein
synthe is is increased.
A role for cyclin kinase inhibitors has been shown in
certain forms of renal hype trophy. Forced overexpre sion
of the cyclin kina it rs p2lC*P1 and p27 induces
hype trophy in mesangial cells in vitro [9]. Glucose-induced
mesangial cell hype trophy in vitro is associated with in-
creased l vels of p2IC [1  [11], and
lowering p27 with antisense abrogates glucose-induced
hype trophy in cultured mesangial cells [ii]. Furthermore,
p21'' [101 and p27 [121 are increased durin  gb-
meru tar hypertrophy in experimental diabetic nephropathy.
Wolf and colleagues previously demonstrated the novel
finding that angiotensin Il-mediated hype trophy in tubular
epithelial cells was associated with increased p27 levels,
while lowering p27 prevented hype trophy [13]. En the
current study, Ha nken et al hav  extended these observa-
tions and ident fied certain intracellular signaling pathways
that increase p27 expression following angiotensin II stim-
ulation [3], providing new insights into how certain growth
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factors interact with specific cell cycle regulatory proteins
to alter cell growth.
A third role for p27 in glomerular cell differentiation has
now been documented as well. During the capillary loop
stage of glomerulogenesis, visceral glomerular epithelial
cells exit the cell cycle, and develop a terminally differen-
tiated phenotype. This coincides with de novo expression of
p27 in GEC [14] and suggests that p27 may be necessary for
glomerular cell differentiation to occur.
A fourth and somewhat unexpected biological function
for p27 is that this cell cycle protein appears to safeguard
renal cells from apoptosis. Inflammatory injury in p27—/—
mice is associated with a marked increase in glomerular
and tubular cell apoptosis compared to controls [81. More
recently we have shown that p27 limits apoptosis in mes-
angial cells and fibroblasts in vitro.
The studies described above characterize a rapidly evolv-
ing and expanding understanding of the role of cyclin
kinase inhibitors in the kidney, a role envisioned as only
anti-proliferative just two years ago. As usual, these find-
ings answer a few questions but raise even more. Is p27 the
kidneys friend or foe' Should we be trying to increase or
decrease p27 levels in renal disease? Why do p27 levels
decrease in one cell type, yet increase in another cell type
in response to the same stimulus? Does the biological
function of p27 differ from one renal cell type to another?
Hannken and colleagues have started to answer some of
these questions, and it is hoped that others will provide
more knowledge in the near future that will bring us several
steps closer to the goal of manipulating these processes to
the benefit of patients with renal disease.
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factors interact with specific cell ycl  regulatory proteins
to alter cell growth.
A thi d role for p27 in glomerular cell differen ation has
now been documented as well. During the capillary loop
stage of glomerulogenesis, viscera  glomerular epithelial
cells exit th  cell ycle, and d velop a terminally differen-
iated phenotype. This coincides with de n vo expression of
p27 in GEC [14] and suggests that p27 may b  necessary for
glomerular cell differen ation to occur.
A fourth and somewhat unexp cted biological function
for p27 is that this cell ycle protein appears to safeguard
renal cells from ap ptosis. Inflammatory injury in p27—/-
mice i  associated with a marked increase in glomerular
and t bular cell a optosis compared t  controls [81. More
r cently we have shown that p27 l mits a optosis in mes-
angial cells and fibroblasts in vitro.
The studies described above characterize  rapidly evolv-
ing and expanding understanding of the role of yclin
kinase inhibitors in the kidney, a role envisioned as only
anti-proliferative just two years ago. A  sual, these find-
ings answer a few questions but raise ven more. Is p27 the
kidneys friend or foe9 Should w  be trying to increase or
decrease p27 l vels in renal disease? Why do p27 l vels
decrease in on  cell type, yet increase i  another cell type
in response to the same stim lus? Does the biological
function of p27 differ from on  renal cell type to another?
Hannken and colleagues have s arted to answer some of
these questions, and it is hoped tha  others will provide
more knowledge in th  near future that will bring us s veral
steps closer o the goal of manipulating these processes to
the b nefit of patients with renal disease.
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